Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):573-579. doi: 10.1097/QAI.0000000000001865.

Natural History of Cervical Intraepithelial Neoplasia-2 in HIV-Positive Women of Reproductive Age.

Author information

1
Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, DC.
2
Department of Medicine, Georgetown University, Washington, DC.
3
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO.
4
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
5
Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC.
6
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA.
7
Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
8
Department of Medicine, University of California, San Francisco, CA.
9
Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY.
10
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

Abstract

OBJECTIVE:

To evaluate the natural history of treated and untreated cervical intraepithelial neoplasia-2 (CIN2) among HIV-positive women.

METHODS:

Participants were women enrolled in the Women's Interagency HIV Study between 1994 and 2013. One hundred four HIV-positive women diagnosed with CIN2 before age 46 were selected, contributing 2076 visits over a median of 10 years (interquartile range 5-16). The outcome of interest was biopsy-confirmed CIN2 progression, defined as CIN3 or invasive cervical cancer. CIN2 treatment was abstracted from medical records.

RESULTS:

Most women were African American (53%), current smokers (53%), and had a median age of 33 years at CIN2 diagnosis. Among the 104 HIV-positive women, 62 (59.6%) did not receive CIN2 treatment. Twelve HIV-positive women (11.5%) showed CIN2 progression to CIN3; none were diagnosed with cervical cancer. There was no difference in the median time to progression between CIN2-treated and CIN2-untreated HIV-positive women (2.9 vs. 2.7 years, P = 0.41). CIN2 treatment was not associated with CIN2 progression in multivariate analysis (adjusted hazard ratio 1.82; 95% confidence interval: 0.54 to 7.11), adjusting for combination antiretroviral therapy and CD4 T-cell count. In HIV-positive women, each increase of 100 CD4 T cells was associated with a 33% decrease in CIN2 progression (adjusted hazard ratio 0.67; 95% confidence interval: 0.47 to 0.88), adjusting for CIN2 treatment and combination antiretroviral therapy.

CONCLUSIONS:

CIN2 progression is uncommon in this population, regardless of CIN2 treatment. Additional studies are needed to identify factors to differentiate women at highest risk of CIN2 progression.

PMID:
30272635
PMCID:
PMC6231968
[Available on 2019-12-15]
DOI:
10.1097/QAI.0000000000001865

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center